ABOUT BREAST CANCER TRIALS
WHO WE ARE
Breast Cancer Trials exists to improve and save the lives of people affected by breast cancer, through clinical trials research.
As the largest, independent, oncology clinical trials research group in Australia and New Zealand, our research program involves multicentre national and international clinical trials and brings together more than 926 members from Australia and New Zealand, at 114 participating institutions. More than 17,170 people have participated in our clinical trials.
Our clinical trials rigorously and scientifically test the efficacy of new breast cancer treatments and prevention strategies. Through collaboration, resources are pooled so that answers to important research questions can be made sooner and with greater scientific integrity for the benefit of everyone diagnosed with this disease.
This research program plays a pivotal role in influencing breast cancer practice globally, contributing to better outcomes and treatments for thousands of women in Australia and New Zealand, and potentially millions more throughout the world. Our research achievements have helped provide evidence which guides treatments for patients every day.
This translates into more lives being saved from breast cancer than ever before.
OUR VISION
Improving and saving the lives of people affected by breast cancer.
OUR MISSION
To conduct the highest quality clinical trials research that improves outcomes for people affected by breast cancer.
OUR VALUES
We Before Me, Curiosity, Empathy and Greatness.
CASE STUDY
Maria is a participant in the TUGETHER clinical trial, which is targeting HER2-positive metastatic breast cancer on multiple levels in an attempt to slow and arrest the progression of this disease.
Developed by Australian researchers, TUGETHER will combine the well-known anti-HER2 therapy Trastuzumab (Herceptin), which works to block the HER2 receptors on the outside of cancer cells, with a new anti-HER2 therapy called Tucatinib, which works by getting inside the cancer cells and blocking the growth signals sent by HER2 receptors. These two anti-HER2 therapies will be combined with Pembrolizumab, an immunotherapy that aids the body’s immune system to identify and kill cancer cells.
It is hoped that the combination of these therapies will provide a new treatment approach for metastatic HER2-positive breast cancer.
TUGETHER will recruit 50 patients from 16 institutions across Australia.